Study leader, Joseph T. Giacino, Ph.D, who now serves as Director of Rehabilitation Neuropsychology at Spaulding Rehabilitation Hospital said, “The results of this study provide convincing evidence that it is possible to increase the speed of recovery from severe traumatic brain injury when treatment is initiated within four months of onset. These findings engender optimism for a medical condition that is often viewed as untreatable.”
The study results pave the way for additional studies of a drug whose therapeutic value was previously undetermined. “Now that we know that amantadine can accelerate neurologic recovery, we need to explore the dose and treatment schedule that provides the greatest and most durable treatment impact,” said study co-leader, John Whyte, M.D., Ph.D, Director of Moss Rehabilitation Research Institute. “Importantly, this study adds to the growing evidence that patients with disorders of consciousness have rehabilitation potential that we are just beginning to tap.”
In addition to JFK Johnson Rehabilitation Institute and MossRehab, nine other rehabilitation institutions participated in the study including:
- Braintree Rehabilitation Hospital in Braintree, MA.
- Bryn Mawr Rehabilitation Hospital in Malvern, PA
- Carolinas Rehabilitation in Charlotte, NC
- Fachkrankenhaus Neresheim Hospital in Neresheim, Germany
- Copenhagen University Hospital in Glostrup, Denmark
- Methodist Rehab Center in Jackson, MS
- Schoen Klinik Bad Aibling in Bad Aibling, Germany
- Sunnyview Rehabilitation Hospital in Schenectady, NY
- Texas Neurorehab Center in Austin, TX
In addition, the Department of Biostatistics in the Mailman School of Public Health at Columbia University in New York City served as the Data Coordinating Center under the direction of Emilia Bagiella, PhD.